Boehringer Ingelheim and BioMed X extend collaboration to discover novel therapeutic concepts for the treatment of psychiatric diseases
Heidelberg (ots)
The BioMed X Innovation Center announced today that they have extended their current collaboration with Boehringer Ingelheim in the field of chronic obstructive pulmonary disease (COPD) to establish a second team of outstanding scientists from around the world to discover novel therapeutic concepts for the treatment of psychiatric diseases. In a joint crowdsourcing approach, Boehringer Ingelheim and BioMed X are inviting early career neuroscientists from leading academic institutions world-wide to submit original project proposals that explore the complex circuit biology at the interface between projection neurons, interneurons and non-neuronal cells for the generation of novel therapeutic concepts. The best ideas and life science talents will be jointly selected by Boehringer Ingelheim and BioMed X to form a new research group within BioMed X's open innovation lab, which is part of the vibrant life science campus of the University of Heidelberg. "We are excited about Boehringer Ingelheim's decision to double their commitment after such a short period of time", said Christian Tidona, founder and Managing Director of BioMed X. "It clearly indicates that our new model is perceived by the pharmaceutical industry as a truly promising external innovation tool." BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility and enabling access to the Heidelberg scientific community and research facilities. Further details of the agreement and financial terms are not disclosed.
Contact:
BioMed X Innovation Center
Eva-Maria Gottmann
Director of Marketing
Im Neuenheimer Feld 583
69120 Heidelberg
Phone: +4962214261110
Fax: +4962214261122